Project the global leukemia burden in patients younger and older than 20 years. by Chengjun Hu (588206)

Subjects:

Leukemia ASDR and SDI for 204 countries and territories in 2021. by Chengjun Hu (588206)

Subjects:

Map of the overall global leukemia burden status, 1990-2021. by Chengjun Hu (588206)

Subjects:

Frontier analysis based on SDI and age-standardized leukemia ASDR per 100,000 population from 1990 to 2021. by Chengjun Hu (588206)

Subjects:

Correlation between HDI and EAPC. by Chengjun Hu (588206)

Subjects:

Global leukemia incidence and EAPC, 1990-2021. by Chengjun Hu (588206)

Subjects:

Global and five SDI regions’ leukemia burden trends, 1990-2021. by Chengjun Hu (588206)

Subjects:

Global Distribution of the Number of Males and Females with Leukemia. by Chengjun Hu (588206)

Subjects:

Leukemia ASDR by SDI for 22 GBD regions from 1990 to 2021. by Chengjun Hu (588206)

Subjects:

Joinpoint regression analysis of global leukemia incidence in males and females from 1990 to 2021. by Chengjun Hu (588206)

Subjects:

Effect of drought and foliar application of calcium on plant height (PH), stem diameter (SD) and fresh leaf weight (FLW) of Pearl millet. by Tauqeer Ahmad Yasir (11457674)

Subjects:

Effect of drought and foliar application of calcium on panicle length (PI), grains per panicle (GPP) and grain weight (GW) of pearl millet. by Tauqeer Ahmad Yasir (11457674)

Subjects:

Effect of ibuprofen (IBU) on COX-2 expression. by Katarina Grossmannova (7543517)

“…In FaDu cells, only the ERK1/2 inhibitor decreased the level of IBU-mediated COX-2 expression.…”

AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves. by Naruyoshi Gyoutoku (22537831)

Subjects:

Logistic regression analysis to predict the efficacy for liver function. by Naruyoshi Gyoutoku (22537831)

Subjects:

Comparison in baseline variables between efficacy group and non-efficacy group. by Naruyoshi Gyoutoku (22537831)

Subjects:

Comparison of ALT (A), AST (B), and Fib-4 index (C) before and after imeglimin treatment in ALT ≥ 25 IU/L and ALT < 25IU/L groups. by Naruyoshi Gyoutoku (22537831)

Subjects:

Clinical characteristics at baseline and at the end of the study. by Naruyoshi Gyoutoku (22537831)

Subjects:

Characterization of green synthesized SeNPs. by Pompido Chilala (21578182)

Subjects:

Minimal inhibition concentration (%) of plant extracts or green synthesized SeNPs. Each sample was tested in triplicates. ND = not detected. by Pompido Chilala (21578182)

Subjects: